Novan Inc (NOVN) Expected to Post Earnings of -$0.32 Per Share

Wall Street analysts expect Novan Inc (NASDAQ:NOVN) to announce earnings per share (EPS) of ($0.32) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Novan’s earnings. The lowest EPS estimate is ($0.33) and the highest is ($0.30). Novan posted earnings of ($0.47) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 31.9%. The firm is expected to issue its next quarterly earnings results on Thursday, November 8th.

According to Zacks, analysts expect that Novan will report full-year earnings of ($1.07) per share for the current financial year, with EPS estimates ranging from ($1.10) to ($1.04). For the next financial year, analysts anticipate that the firm will report earnings of ($1.17) per share, with EPS estimates ranging from ($1.49) to ($0.84). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow Novan.

Novan (NASDAQ:NOVN) last announced its earnings results on Wednesday, August 8th. The company reported ($0.29) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.29). Novan had a negative return on equity of 608.09% and a negative net margin of 1,061.54%. The company had revenue of $0.65 million for the quarter, compared to analyst estimates of $0.60 million.

A number of brokerages have recently weighed in on NOVN. Zacks Investment Research upgraded Novan from a “hold” rating to a “buy” rating and set a $3.00 price target for the company in a report on Saturday, August 25th. Piper Jaffray Companies reiterated a “buy” rating and issued a $6.00 price target on shares of Novan in a report on Friday, July 20th. Finally, HC Wainwright began coverage on Novan in a report on Friday, October 26th. They issued a “buy” rating and a $8.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $7.75.

Shares of NASDAQ NOVN traded up $0.07 during trading on Wednesday, reaching $2.64. The stock had a trading volume of 11,134 shares, compared to its average volume of 32,626. Novan has a one year low of $2.27 and a one year high of $6.23. The company has a market capitalization of $66.40 million, a price-to-earnings ratio of -1.14 and a beta of 1.17.

In other Novan news, CEO G. Kelly Martin purchased 30,000 shares of the firm’s stock in a transaction dated Tuesday, August 21st. The stock was bought at an average price of $2.71 per share, with a total value of $81,300.00. Following the completion of the purchase, the chief executive officer now owns 30,000 shares in the company, valued at approximately $81,300. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Robert Alexander Ingram purchased 50,000 shares of the firm’s stock in a transaction dated Friday, September 28th. The stock was acquired at an average cost of $2.84 per share, with a total value of $142,000.00. Following the purchase, the director now owns 119,777 shares of the company’s stock, valued at approximately $340,166.68. The disclosure for this purchase can be found here. In the last three months, insiders bought 110,000 shares of company stock valued at $303,800. Company insiders own 8.83% of the company’s stock.

An institutional investor recently raised its position in Novan stock. Renaissance Technologies LLC increased its position in Novan Inc (NASDAQ:NOVN) by 83.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 59,000 shares of the company’s stock after buying an additional 26,800 shares during the quarter. Renaissance Technologies LLC owned about 0.23% of Novan worth $173,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 11.67% of the company’s stock.

About Novan

Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.

Featured Story: Bear Market – How and Why They Occur

Get a free copy of the Zacks research report on Novan (NOVN)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Novan (NASDAQ:NOVN)

Receive News & Ratings for Novan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novan and related companies with's FREE daily email newsletter.

Leave a Reply